Project Grant R01AG092823
Award Date
6/1/25
Completion Date
3/31/30
Dollars Obligated
$835K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $805,738 in funding to the Battelle Memorial Institute's Pacific Northwest National Laboratory Division, operating as Pacific NW National, to conduct research on the role of brain lipoproteins in the development of Alzheimer's disease. The key objectives of this 5-year project are to: 1) assess the impact of different apolipoprotein E (ApoE) isoforms on the distribution, composition, and...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating peptides...
The National Institute on Aging (NIA) awarded a $506,451 Project Grant under CFDA 93.866, the Aging Research federal grant program, to 3P Biotechnologies, Inc. The goal of this 1-year award is to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, such as Alzheimer's disease (AD). The key products or services to be delivered include: Optimizing the delivery of siRNA against the inflammatory regulator NF-kB (siNF-kB)...
This $504,732 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The awardee, Aphios Corp, will (1) nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, and (2) evaluate the impact of the nanoparticles on in vitro models of brain inflammation and blood-brain barrier penetration. The project aims to identify optimal nanoparticle candidates...
This $949,062 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Somatoceutics LLC aims to develop a novel, non-toxic nanomaterial for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and related dementias. The key objectives are to: Optimize and standardize the assembly of SMC-101 nanotubes, a natural peptide-based nanomaterial, to load with drugs and demonstrate their ability to transcytose the blood-brain barrier in vitro....
This $745,765 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York aims to investigate the effects of Alzheimer's disease (AD) risk genes and aging on human microglia activity and lipid metabolism. The key focus is on understanding how genetic variants associated with increased AD risk or longevity may impact microglia's ability to clear cholesterol/lipid-rich cellular debris, a critical...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $919,106 supports research to discover and optimize "APOE4 correctors" for the treatment of Alzheimer's disease. The award recipient, Sanford Burnham Prebys Medical Discovery Institute, will leverage advanced cellular assays, including a novel split nano-luciferase BITSA, to screen for small molecule compounds that can stabilize the APOE4 protein and make it functionally...
This $843,806 Cooperative Agreement award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop and evaluate blood-brain barrier (BBB) crossing lipid nanoparticles (BLNPs) for efficient delivery of nucleic acid-based therapeutics to the brain. The project, led by the Icahn School of Medicine at Mount Sinai (ISMMS), seeks to synthesize and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $295,000 to Florida International University (FIU) to develop biotherapeutic nanogels for the treatment of Alzheimer's disease. The project aims to improve the nanogels' ability to cross the blood-brain barrier and evaluate their efficacy in ameliorating oxidative stress, amyloid and tau pathology, neuroinflammation, and cognitive decline in an Alzheimer's disease mouse model. Key deliverables...
This federal Project Grant award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), is supporting research focused on optimizing and evaluating a brain-permeable CRISPR-based therapy for editing the APOE4 gene associated with Alzheimer's disease (AD). The $751,442 award to the University of California, Los Angeles (UCLA) aims to develop a synthetic exosome (SE)-encapsulated CRISPR system capable of crossing the blood-brain barrier and editing APOE4 to the less...